CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Immunopharmacologic Monitoring of Therapeutic Serum Antibodies (Therapeutic Drug Monitoring for Biologics)

This policy governs coverage for serum drug level and anti-drug antibody testing (therapeutic drug monitoring, TDM) for biologic therapies, specifying indications, limitations, and which drugs and diagnoses meet or do not meet coverage criteria for BlueCross BlueShield of Tennessee.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyImmunopharmacologic Monitoring of Therapeutic Serum Antibodies

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionRequest prior authorization indicating IBD diagnosis and that testing is for anti‑TNF, vedolizumab, or ustekinumab with proposed frequency.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

q2 weeksIBD testing frequency

Not coveredNon‑IBD TDM

10Drugs listed

>2 µg/mLIFX trough target

10–15 µg/mLDiscontinue threshold (IFX)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Therapeutic Drug Monitoring

TDM coverage — IBD

Covered when ALL of the following are met for IBD:

IBD TDM coverage: For individuals with inflammatory bowel disease (Crohn's disease or ulcerative colitis), measurement of drug and/or anti‑drug antibody concentrations for anti‑TNF therapies, vedolizumab, or ustekinumabfrequency: once every two weeks

Meets coverage criteria for IBD only

TDM not covered — non-IBD indications

Not covered for non-IBD inflammatory conditions:

Non-IBD TDM excluded: For individuals with conditions other than IBD (e.g., spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis), drug and/or antibody concentration testing for anti‑TNF therapies DOES NOT MEET COVERAGE CRITERIA

Explicit denial for non‑IBD indications

Not covered — specific drugs outside covered indications

Not covered for other situations:

Other situations not covered: Measurement of serum drug levels and/or anti‑drug antibodies does not meet coverage criteria for the following drugs (alone or combination) when used outside the IBD indications specified as covered: adalimumab, certolizumab, etanercept, golimumab, infliximab, infliximab‑dyyb, infliximab‑abda, rituximab, ustekinumab, vedolizumab

Policy lists these drugs explicitly as not covered outside stated indications

Appropriate clinical indications (consensus/society-aligned)

Covered when testing is ordered in specific clinical scenarios consistent with society guidance:

Main clinical scenarios: Therapeutic drug monitoring is appropriate when ordered in these IBD clinical scenarios: (1) responders at the end of induction for anti‑TNFs, vedolizumab, or ustekinumab; (2) at least once during maintenance for patients on anti‑TNF therapy (and per consensus statements, at least once during maintenance for vedolizumab and ustekinumab when indicated); (3) primary nonresponders at end of induction; and (4) patients with confirmed secondary loss of response

Based on AGA and consensus statement (Papamichael et al., 2019)

TDM Coverage Criteria

Covered when clinical indications and measured concentrations align with consensus recommendations:

Reactive TDM indications: Reactive TDM should be performed in patients with confirmed primary non‑response or secondary loss of response to anti‑TNF therapy, vedolizumab, or ustekinumab prior to switching therapies

Consensus agreement (100% for many statements)

Infliximab-specific reactive guidance: Do not consider treatment discontinuation for secondary loss of response to infliximab until a drug concentration of at least 10–15 μg/mL is achieved>=10–15 μg/mL

Consensus statement recommendation

Proactive TDM is appropriate post‑induction and at least once during maintenance for anti‑TNF therapy; proactive monitoring may be most useful after reactive TDM or in more severely active patients or those with higher drug clearance

High consensus for anti‑TNF agents; less evidence for non‑anti‑TNF biologics

Supporting evidence (no explicit coverage rules in these chunks)

Evidence and guideline references relevant to TDM

Evidence sources: References include society guidelines (AGA, ACG), consensus statements, systematic reviews, randomized trials, cost‑effectiveness analyses, and assay validation studies that inform TDM utility and target concentrations

Cited works include Papamichael et al. 2019, Vande Casteele et al. 2017, Syversen et al. 2021, NICE guidance, and multiple pharmacokinetic and assay studies

Drug and/or antibody concentration testing for anti-TNF therapies, vedolizumab, or ustekinumab is excluded from coverage when ordered for indications other than inflammatory bowel disease (IBD). The policy explicitly states that testing for conditions such as spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis does not meet coverage criteria, and that measurement of serum drug levels or antibodies for the listed drugs in situations not specified as covered is not covered (see list of drugs in the policy).

Major gastroenterology societies do not endorse routine proactive therapeutic drug monitoring (TDM) for all unselected patients in remission. The AGA and ACG guidance emphasize reactive TDM in adults with active disease and note that the benefit of routine proactive monitoring in quiescent patients is uncertain or unsupported by current evidence.

For vedolizumab and ustekinumab, current data are insufficient to define specific induction or maintenance concentration targets. Consensus statements indicate that beyond confirming a detectable drug level, specific therapeutic thresholds for induction and maintenance have not been established.

This section contains references and evidence summaries relevant to therapeutic drug monitoring, including society guidelines, systematic reviews, randomized trials, cost-effectiveness analyses, and assay validation studies. Cited works include ACG and AGA guidelines, Papamichael et al. (2019), Syversen et al., NICE guidance, and multiple pharmacokinetic and assay validation publications.

Measurement of serum drug concentrations and/or anti-drug antibodies is considered to not meet coverage criteria when performed outside the specified conditions in this policy (for example, for non-IBD indications or for drugs/situations not identified as covered). Requests must meet the policy's IBD-specific criteria and timing to be eligible for coverage.

Use of ELISA-based assays for routine, non-research therapeutic monitoring has been judged to have insufficient evidence in some contexts. NICE concluded that ELISA kits show promise but that there is currently insufficient evidence to recommend routine adoption for Crohn's disease and rheumatoid arthritis, and recommended that ELISA testing be part of research or data collection.

When high-titer anti-drug antibodies are identified as the cause of secondary loss of response, dose escalation is not recommended. Consensus guidance states that such patients should be switched to a different therapy (and consider adding an immunomodulator if switching within class) rather than attempting dose escalation.

The referenced chunks in this part of the document provide bibliographic material and do not contain explicit 'not medically necessary' policy statements; they serve as supporting references for the policy.

Drugs and Codes Referenced

Drugs referenced for monitoringmixed

adalimumab	drug named in policy
certolizumab	drug named in policy
etanercept	drug named in policy
golimumab	drug named in policy
infliximab	drug named in policy
infliximab-dyyb	biosimilar named in policy
infliximab-abda	biosimilar named in policy
rituximab	drug named in policy
ustekinumab	drug named in policy
vedolizumab	drug named in policy

Covered CPT/HCPCS Codes (reference)CPT | HCPCS

80145	Adalimumab.
80230	Infliximab.
80280	Vedolizumab.
80299	Quantitation of therapeutic drug, not elsewhere specified.
82397	Chemiluminescent assay.
84999	Unlisted chemistry procedure.
0514U	Immunoassay for quantitative determination of adalimumab levels (Procise ADL™).
0515U	Immunoassay for quantitative determination of infliximab levels (Procise IFXT™).

Infliximab trough concentration — maintenance trough thresholds and associated outcomes

Maintenance trough associated with remissionInfliximab trough >2 µg/mL during maintenance is associated with a greater probability of clinical remission and mucosal healing

LFA-derived mucosal healing thresholdInfliximab trough ≥2.1 µg/mL associated with mucosal healing (Van Stappen et al., LFA validation)

Post-induction target used in proactive regimensProactive TDM studies aimed for IFX trough 3–7 µg/mL (Crohn’s disease) and 5–10 µg/mL (ulcerative colitis)

Adalimumab trough level — cited threshold associated with failure of two anti-TNF agents

Adalimumab trough linked to multi‑agent failure>4.9 µg/mL adalimumab trough levels associated with failure of two anti‑TNF agents (adalimumab and infliximab) — consider switching drug class

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization: IBD-only testing

Prior authorization is required for therapeutic drug monitoring (TDM) when the testing is performed for inflammatory bowel disease (IBD) indications. Prior authorization requests should document the IBD diagnosis and that testing is being requested to guide therapy for covered biologics.

Coverage for drug and/or antibody concentration testing is limited to individuals with IBD.
Prior authorization submissions should indicate the diagnosis (IBD) and that testing is for a covered biologic.

Note

Prior Authorization Not Specified in Referenced Text

Some referenced guidelines and literature do not specify prior authorization requirements; these sources provide clinical context and recommendations but do not themselves mandate payer authorization processes.

Guideline and study citations are informational — they do not state payer-level prior authorization rules.
Providers should follow payer-specific authorization procedures even when guidelines recommend TDM.

Background: Therapeutic Drug Monitoring and Biologic Therapies

Tumor necrosis factor (TNF) inhibitors and other biologic therapies commonly used to treat immune-mediated inflammatory diseases include infliximab, adalimumab, certolizumab, golimumab, etanercept, ustekinumab, and vedolizumab. Formation of anti-drug antibodies and low drug trough concentrations are mechanisms that can reduce efficacy and contribute to secondary loss of response; therapeutic drug monitoring (measurement of trough drug levels and anti-drug antibodies) is used to inform decisions such as dose optimization or switching therapies, particularly in inflammatory bowel disease (IBD).

Definitions and Key Terms

ADAbs — anti-drug antibody status definition

DefinitionAnti‑drug antibody status (ADAbs): antibodies developed against a therapeutic biologic that can reduce efficacy and cause adverse effects

Clinical relevanceADAbs are more clinically relevant when trough drug concentrations are undetectable

Assay considerationsCommercial assays vary; interpretation should consider assay used and consistency over time

TDM — Therapeutic drug monitoring definition

DefinitionTherapeutic drug monitoring (TDM): measurement of serum drug trough concentrations and anti‑drug antibodies to guide management decisions

PurposeTDM informs dosing adjustments, switching biologics, and evaluation of loss of response

Evidence, Guidelines, and Vendor Resources

The evidence base cited in the policy includes clinical society guidelines (ACG, AGA, NICE), systematic reviews and meta-analyses, randomized controlled trials, cost-effectiveness analyses, and assay validation studies. Representative references include ACG clinical guidelines on Crohn's disease and dosing/monitoring of TNF inhibitors, Papamichael et al. (2019) consensus statements on TDM in IBD, and several studies evaluating proactive versus reactive TDM and assay performance.

Additional bibliographic references supporting the policy are listed here and include clinical reviews, consensus statements, and original research on TDM assays and outcomes (examples: Papamichael et al. 2019; NICE guidance; Lichtenstein et al. ACG guideline; systematic reviews of infliximab levels and clinical outcomes). These references provide the scientific context for the coverage determinations but do not themselves establish coverage rules.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyImmunopharmacologic Monitoring of Therapeutic Serum Antibodies

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionRequest prior authorization indicating IBD diagnosis and that testing is for anti‑TNF, vedolizumab, or ustekinumab with proposed frequency.

SourceLink

On This Page

Golimumab concentrations: Target trough guidance: minimum concentration at week 6 ≥2.5 μg/mL and maintenance trough in remission >1 μg/mL>=2.5 μg/mL (week 6); >1 μg/mL (maintenance)

Consensus panel statements

Vedolizumab and ustekinumab guidance: For vedolizumab and ustekinumab the primary laboratory confirmation is detectable drug; current evidence is insufficient to define specific induction and maintenance concentration targets beyond detectabilitydetectable

Insufficient data to define quantitative targets

Optimization response contextLow ADA trough without AAA predictive of response to ADA optimization in majority of cases

Implication of detectable AAALow ADA with detectable anti‑adalimumab antibodies (AAA) is associated with ADA failure and suggests switching to infliximab

Biologic-specific trough / target concentrations — summary of drug-specific targets

Infliximab targetsPost‑induction minimal trough >3 µg/mL; concentrations >7 µg/mL associated with increased likelihood of mucosal healing; generally do not abandon IFX for active disease unless >10 µg/mL

Adalimumab targetsWeek 4 minimum ≥5 µg/mL; concentrations >7 µg/mL associated with mucosal healing; maintenance trough >5 µg/mL; avoid abandoning unless >10 µg/mL

Certolizumab targetsWeek 6 minimum >32 µg/mL; maintenance trough for remission ~15 µg/mL

Golimumab targetsWeek 6 minimum ≥2.5 µg/mL; maintenance trough in remission >1 µg/mL

Therapeutic drug concentration thresholds — golimumab and infliximab numeric thresholds referenced

Golimumab numeric thresholdsMinimum trough concentration at week 6 ≥2.5 µg/mL; maintenance trough in remission >1 µg/mL

Infliximab discontinuation thresholdDo not consider discontinuation for secondary loss of response to infliximab until drug concentration of at least 10–15 µg/mL is achieved

Proactive TDM targets summaryProactive regimens have targeted IFX troughs of ~3–7 µg/mL (CD) and 5–10 µg/mL (UC) based on clinical studies

Denial Risk

Coverage Limited to IBD

Coverage is restricted to IBD: measurement of serum drug levels and/or antibodies meets coverage criteria only for individuals with inflammatory bowel disease (IBD). Testing for other indications (e.g., RA, psoriatic disease) does not meet coverage.

Testing for conditions other than IBD (e.g., spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis) DOES NOT MEET COVERAGE CRITERIA.
For IBD, testing frequency guidance (e.g., once every two weeks for certain settings) appears in clinical sections — prior auth must reflect covered indication.

Denial Risk

Denial Risk When Outside Guideline-Recommended Use

Requests for routine proactive monitoring outside guideline-recommended scenarios may face coverage denial; proactive TDM is variably supported and often limited to guided clinical contexts.

AGA/ACG make limited or conditional recommendations for proactive TDM; routine proactive monitoring in unselected patients is not broadly supported.
Claims for proactive TDM without documented clinical rationale (active disease, loss of response, or other guideline-supported reason) are at increased risk for denial.

Documentation Required

Treatment Discontinuation / Switching: Do Not Proceed Until Adequate Concentration Assessed

Treatment discontinuation or switching should generally not be performed until adequate drug concentration thresholds are assessed and, where applicable, an adequate trough concentration has been achieved.

Do not discontinue or switch therapy for secondary loss of response until infliximab concentrations reach suggested thresholds (e.g., 10-15 μg/mL) when applicable.
Reactive TDM is recommended prior to switching therapy for primary non-response or secondary loss of response for vedolizumab and ustekinumab.

Note

No Explicit Denial Triggers in Referenced Text

The cited references and guidelines in this section do not contain explicit payer denial triggers; they provide clinical recommendations that inform but do not define authorization decisions.

No single citation here specifies explicit claim denial rules — payer policy determines coverage enforcement.
Use guideline statements to support medically necessary documentation, but expect payer-specific operational rules.

Documentation Required

Follow-up and Assay Consistency

Follow patients longitudinally with the same TDM assay when possible to ensure comparability of results; document the assay used and serial results in the medical record.

Document assay type and vendor when submitting results or prior authorization requests.
Consistent assay use is recommended until assays are standardized/cross-validated.

Note

References Include Laboratory / Vendor Resources

References include vendor and laboratory resources describing available TDM assays; providers may use these resources for assay details but must include assay information in documentation.

Vendor/laboratory references include Prometheus, ProciseDx (Procise ADL™, Procise IFXT™), and Theradiag/Inform Diagnostics.
Procedure codes for proprietary tests (e.g., 0514U, 0515U) and general TDM assays are listed in the coding section — providers should use appropriate codes when submitting claims.

Note

Therapeutic Decision Context

Therapeutic decisions should be based on clinical evidence of inadequate control; TDM is intended to inform whether to adjust dose, add immunomodulator, or switch biologic rather than reflexively escalate treatment.

Adjust or switch biologic DMARDs only when clinical evidence indicates remission or low disease activity is not achieved or maintained.
When switching within class for secondary loss of response due to antibodies, consider adding an immunomodulator to the subsequent anti-TNF therapy.

Step Therapy

TDM Informs Step Therapy Decisions

TDM results commonly inform step therapy decisions such as dose escalation, continuation, or switching biologics; reactive TDM is recommended to identify the reason for loss of response and guide next steps.

TDM may lead to treatment escalation, switching biologics, or maintaining current therapy depending on drug levels and antibody status.
Studies show TDM-informed management can increase mucosal healing and reduce surgery in certain IBD populations.

Prior Authorization

Management of Secondary Loss of Response with High-Titer Antibodies

Patients with secondary loss of response due to high-titer anti-drug antibodies should not be dose-escalated; instead, they should be switched to a different therapy (within-class or out of class).

High-titer anti-drug antibodies are a rationale for switching rather than dose escalation.
When switching due to antibodies, adding an immunomodulator to the new anti-TNF may be recommended.

Step Therapy

No Step Therapy Rules Provided Here

No step therapy rules are provided in the cited literature here; studies compare proactive vs reactive TDM strategies and individualized therapy versus dose intensification, but payer-level step edits are not specified.

Clinical trials and cost-effectiveness analyses inform clinical practice but do not define payer step therapy edits.
Providers should consult plan-specific step therapy rules in addition to using TDM to guide clinical decisions.

Assay consistencyPatients should be followed using the same TDM assay when possible until assays are standardized

Trough concentration — definition and note about measurement timing/targets

DefinitionTrough concentration: the serum drug concentration measured at the end of a dosing interval (typically within 24 hours before the next scheduled dose)

Clinical targetsMinimal trough targets are specified for certain biologics (e.g., infliximab post‑induction >3 µg/mL; maintenance >3 µg/mL)

Interpretation noteTrough timing and assay used are important for interpretation of results

High-titer anti-drug antibodies — assay-specific thresholds (examples)

Assay‑specific high‑titer examplesFor anti‑infliximab, ANSER high‑titer cutoff = 10 U/mL; RIDASCREEN cutoff = 200 ng/mL; InformTx/Lisa Tracker cutoff = 200 ng/mL

Clinical implicationHigh‑titer anti‑drug antibodies at trough typically necessitate a change of therapy rather than dose escalation

Data limitationsBeyond the homogeneous mobility shift assay, insufficient data exist to define universal high‑titer cutoffs for other assays or biologics

TDM (alternate) — restatement of TDM definition in other chunks

Restated definitionTherapeutic drug monitoring (TDM): measurement of drug concentration and antibodies to biologic therapies to guide treatment decisions over time

RecommendationUse TDM reactively in confirmed primary non‑response or secondary loss of response; proactive post‑induction monitoring is recommended for anti‑TNFs by consensus

Assay adviceFollow patients with the same assay when possible and document the assay used

Low-titer anti-drug antibodies — HM$A example threshold and implications

HMSA low‑titer exampleLow‑titer anti‑infliximab antibodies (HMSA) defined as <10 U/mL — may be overcome by treatment optimization

Clinical actionLow‑titer antibodies can sometimes be managed with dose escalation, interval shortening, or adding an immunomodulator

AssociationFormation of antibodies to infliximab or adalimumab can be reduced by concomitant immunomodulators

Therapeutic Drug Monitoring (TDM) — general definition to accompany policy

General definitionTherapeutic Drug Monitoring (TDM): measurement of serum drug concentrations and anti‑drug antibodies for biologic agents to inform dosing adjustments and management decisions

ScopeUsed to guide escalation, switching, or confirmation of mechanism of nonresponse in IBD; evidence and recommendations vary by disease and drug

Assay variabilityAssays and thresholds vary by platform; consistent assay use and documentation recommended